{"id":398070,"date":"2020-12-11T06:44:27","date_gmt":"2020-12-11T11:44:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398070"},"modified":"2020-12-11T06:44:27","modified_gmt":"2020-12-11T11:44:27","slug":"kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/","title":{"rendered":"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>SUZHOU, <span class=\"xn-location\">China<\/span>, <span class=\"xn-chron\">Dec. 11, 2020<\/span> \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited\u00a0(HKEX: 9939)\u00a0is\u00a0pleased to update\u00a0the preliminary analysis <span id=\"spanHghlt78b4\">of the Proxalutamide&#8217;s\u00a0clinical trial for COVID-19<\/span>.<\/p>\n<p>Proxalutamide is a new androgen receptor (AR) antagonist developed in\u00a0by\u00a0Kintor Pharmaceutical\u00a0and is currently undergoing phase I-III clinical trials in <span class=\"xn-location\">China<\/span> and the\u00a0US for the treatment of prostate cancer and breast cancer. Following the outbreak of COVID-19, the company\u00a0found that Proxalutamide could limit the expression of ACE-2 and TMPRSS2,\u00a0which plays a critical role for SARS-CoV-2 to bind and enter host cells in the lung.<\/p>\n<p>The Clinical Trial\u00a0is a randomized, double-blind and placebo-controlled clinical trial, designed\u00a0to explore the role of anti-androgen agent\u00a0for the treatment of COVID-19. It is an investigator initiated trial (IIT). The preliminary analysis included 319 enrolled subjects. The co-primary endpoints of the clinical trial are the percentage of subjects hospitalized with COVID-19 and the COVID-19 Ordinal Outcome Scale\u00a0(a 7-point ordinal scale published by the\u00a0World Health Organization, such as\u00a0mechanical ventilation usage\u00a0and\u00a0death)\u00a0in 30 days. The preliminary outcome of the trial showed that the hospitalization rate\u00a0was\u00a00.8% for the\u00a0Proxalutamide arm,\u00a0compared to 27.0% for the control arm,\u00a0the percentage of mechanical ventilation usage was 0% for Proxalutamide arm versus 9.0% for the control arm, and the percentage of death was 0% for Proxalutamide arm versus 2.0% for the control arm.\u00a0Both co-primary efficacy endpoints were achieved. The final clinical study report of the trial is expected in January 2021.\u00a0<\/p>\n<p>The table below is the comparison between Proxalutamide arm and control arm in terms of percentage of positive in rtPCR test between day 0 and day 30 as of <span class=\"xn-chron\">December 8<\/span>, 2020.\u00a0The Proxalutamide arm has shown greater reduction of viral load starting from\u00a0day 7, and this trend continued until the results of day 30.\u00a0The rtPCR test , so called RT-PCR test, is a real-time reverse transcription polymerase chain reaction test for the qualitative detection of nucleic acid from SARS-CoV-2, of which positive results are indicative of the presence of SARS-CoV-2 RNA.\u00a0<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prnsbts prnrbrs prnvab prnsbbs prnpl8 prnsbls prnpr14\">\n              \n            <\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Proxalutamide arm<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Control arm<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">rtPCR positive (%) Day 0<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">100%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">100%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">rtPCR positive (%) Day 3<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">100%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">100%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">rtPCR positive (%) Day 7<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">42.5%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">93.8%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">rtPCR positive (%) Day 14<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">15.0%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">56.2%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">rtPCR positive (%) Day 30<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">10.0%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">43.8%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>Dr. Tong Youzhi, the founder, Chairman and CEO of Kintor Pharmaceutical, said, &#8220;Proxalutamide, as an AR antagonist, is used for the treatment of tumor and AR related non-tumor diseases.\u00a0<span id=\"spanHghltc6d9\">We<\/span> are glad to see the positive results in COVID-19 clinical trials with Proxalutamide, which is expected to reduce the probability of the progression from mild to severe in COVID-19 patients by lowering the expression of TMPRSS2 and ACE-2 proteins. We are actively initiating MRCT phase III clinical trials in countries such as the US and <span class=\"xn-location\">China<\/span>, and hope to obtain an emergency use authorization (EUA) , in this way more COVID-19 patients would benefit from Proxalutamide.&#8221;<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial-301191153.html\">http:\/\/www.prnewswire.com\/news-releases\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial-301191153.html<\/a><\/p>\n<p>SOURCE  Kintor Pharmaceutical Limited<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN21277&amp;Transmission_Id=202012110641PR_NEWS_USPR_____CN21277&amp;DateId=20201211\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SUZHOU, China, Dec. 11, 2020 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited\u00a0(HKEX: 9939)\u00a0is\u00a0pleased to update\u00a0the preliminary analysis of the Proxalutamide&#8217;s\u00a0clinical trial for COVID-19. Proxalutamide is a new androgen receptor (AR) antagonist developed in\u00a0by\u00a0Kintor Pharmaceutical\u00a0and is currently undergoing phase I-III clinical trials in China and the\u00a0US for the treatment of prostate cancer and breast cancer. Following the outbreak of COVID-19, the company\u00a0found that Proxalutamide could limit the expression of ACE-2 and TMPRSS2,\u00a0which plays a critical role for SARS-CoV-2 to bind and enter host cells in the lung. The Clinical Trial\u00a0is a randomized, double-blind and placebo-controlled clinical trial, designed\u00a0to explore the role of anti-androgen agent\u00a0for the treatment of COVID-19. It is an investigator initiated trial (IIT). The preliminary analysis included 319 enrolled &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398070","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#039;s Clinical Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#039;s Clinical Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SUZHOU, China, Dec. 11, 2020 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited\u00a0(HKEX: 9939)\u00a0is\u00a0pleased to update\u00a0the preliminary analysis of the Proxalutamide&#8217;s\u00a0clinical trial for COVID-19. Proxalutamide is a new androgen receptor (AR) antagonist developed in\u00a0by\u00a0Kintor Pharmaceutical\u00a0and is currently undergoing phase I-III clinical trials in China and the\u00a0US for the treatment of prostate cancer and breast cancer. Following the outbreak of COVID-19, the company\u00a0found that Proxalutamide could limit the expression of ACE-2 and TMPRSS2,\u00a0which plays a critical role for SARS-CoV-2 to bind and enter host cells in the lung. The Clinical Trial\u00a0is a randomized, double-blind and placebo-controlled clinical trial, designed\u00a0to explore the role of anti-androgen agent\u00a0for the treatment of COVID-19. It is an investigator initiated trial (IIT). The preliminary analysis included 319 enrolled &hellip; Continue reading &quot;Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T11:44:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial\",\"datePublished\":\"2020-12-11T11:44:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/\"},\"wordCount\":475,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN21277&amp;sd=2020-12-11\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/\",\"name\":\"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN21277&amp;sd=2020-12-11\",\"datePublished\":\"2020-12-11T11:44:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN21277&amp;sd=2020-12-11\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN21277&amp;sd=2020-12-11\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial - Market Newsdesk","og_description":"PR Newswire SUZHOU, China, Dec. 11, 2020 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited\u00a0(HKEX: 9939)\u00a0is\u00a0pleased to update\u00a0the preliminary analysis of the Proxalutamide&#8217;s\u00a0clinical trial for COVID-19. Proxalutamide is a new androgen receptor (AR) antagonist developed in\u00a0by\u00a0Kintor Pharmaceutical\u00a0and is currently undergoing phase I-III clinical trials in China and the\u00a0US for the treatment of prostate cancer and breast cancer. Following the outbreak of COVID-19, the company\u00a0found that Proxalutamide could limit the expression of ACE-2 and TMPRSS2,\u00a0which plays a critical role for SARS-CoV-2 to bind and enter host cells in the lung. The Clinical Trial\u00a0is a randomized, double-blind and placebo-controlled clinical trial, designed\u00a0to explore the role of anti-androgen agent\u00a0for the treatment of COVID-19. It is an investigator initiated trial (IIT). The preliminary analysis included 319 enrolled &hellip; Continue reading \"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-11T11:44:27+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial","datePublished":"2020-12-11T11:44:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/"},"wordCount":475,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/","name":"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11","datePublished":"2020-12-11T11:44:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN21277&amp;sd=2020-12-11"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-preliminary-results-from-the-proxalutamides-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide&#8217;s Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398070"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398070\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}